Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma

NCT07109336 is registered in ClinicalTrials.gov with Zhongda Hospital as lead sponsor.

NCT NCT07109336
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07109336 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Development and Prospective Validation of a Heterogeneous Treatment Effect-Based Decision Model for Transarterial Chemoembolization Combined With or Without Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
Lead sponsor
Zhongda Hospital
Phase
Not applicable
Overall status
Completed
Start date
August 1, 2025
Completion date
August 30, 2026
Enrollment
236 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hcc - hepatocellular carcinoma